Literature DB >> 18829860

Endoscopic vitrectomy improves outcomes of Seoul-type keratoprosthesis exchange in rabbit model.

Sang-Mok Lee1, Mee-Kum Kim, Joo Youn Oh, Jang-Won Heo, Mi-Sun Shin, Moo-Suk Lee, Won-Ryang Wee, Jin-Hak Lee.   

Abstract

PURPOSE: To investigate the efficacy of an endoscopic vitrectomy in Seoul-type keratoprosthesis (S-Kpro) exchange procedures.
METHODS: Nine S-Kpro-implanted rabbit eyes were enrolled in the S-Kpro exchange. Six eyes underwent an antecedent vitrectomy by an endoscopic system and then the S-Kpro exchange (endoscopy group). In the other three eyes, previously placed S-Kpros were removed, and a conventional vitrectomy was performed using the Eckardt keratoprosthesis, followed by an implantation of new S-Kpros (Eckardt group). All eyes were evaluated with slit lamp biomicroscopy and ultrasonography weekly to evaluate the time up to the development of the total retinal detachment (RD).
RESULTS: Vitreous traction membranes were found around the prolene haptics of the fixation sites in all the S-Kpro implanted rabbits; they were excised precisely through an endoscopic view in the endoscopy group. The mean survival time up to the RD development was 9.75 +/- 4.70 weeks in the endoscopy group. In contrast, total retinal detachment or dialysis over 180 degrees developed during surgery in all three eyes in the Eckardt group.
CONCLUSIONS: Antecedent endoscopic vitrectomy was safe and effective for the S-Kpro exchange in a rabbit model by removing the vitreous traction near the haptics before the exchange procedures.

Entities:  

Mesh:

Year:  2008        PMID: 18829860     DOI: 10.1167/iovs.08-1802

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  1 in total

1.  Matrix metalloproteinase-9 expression in the Seoul-type keratoprosthesis implanted corneas with concurrent cultivated autologous oral mucosal epithelial cell transplantation.

Authors:  Sang-Mok Lee; Mee-Kum Kim; Mi-Sun Shin; Won-Ryang Wee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-18       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.